These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34422362)

  • 1. PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
    Shen X; Wang Y; Jin Y; Zheng Q; Shen L; Chen Y; Li Y
    J Thorac Dis; 2021 Jul; 13(7):4360-4370. PubMed ID: 34422362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
    Matsuoka H; Araya T; Kita T; Terada N; Yamamura K; Nishikawa S; Tambo Y; Sone T; Kimura H; Ooi A; Kasashima S; Kawashima A; Kasahara K
    J Cancer; 2021; 12(15):4478-4487. PubMed ID: 34149911
    [No Abstract]   [Full Text] [Related]  

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 22C3-PD-L1 Expression Between Paired Tumor Paraffin Blocks of Surgical Resection Specimens of Nonsmall Cell Lung Cancer.
    Jiang L; Zhang J; Xu H; Liu H; Wang C; Chen X
    Appl Immunohistochem Mol Morphol; 2023 Jan; 31(1):33-39. PubMed ID: 36367192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
    Saito Y; Horiuchi S; Morooka H; Ibi T; Takahashi N; Ikeya T; Shimizu Y; Hoshi E
    J Thorac Dis; 2019 Dec; 11(12):4982-4991. PubMed ID: 32030214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
    Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
    J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
    Hwang DM; Albaqer T; Santiago RC; Weiss J; Tanguay J; Cabanero M; Leung Y; Pal P; Khan Z; Lau SCM; Sacher A; Torlakovic E; Cheung C; Tsao MS
    J Thorac Oncol; 2021 Sep; 16(9):1490-1500. PubMed ID: 33915250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S; Fujiwara Y; Tsuta K; Utsumi H; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Sasada S; Watanabe S; Asamura H; Tamura T; Ohe Y
    Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
    Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV
    J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
    Chen M; Xu Y; Zhao J; Li J; Liu X; Zhong W; Wang M
    Thorac Cancer; 2021 Sep; 12(17):2339-2344. PubMed ID: 34291566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    Gompelmann D; Sinn K; Brugger J; Bernitzky D; Mosleh B; Prosch H; Geleff S; Blessing A; Tiefenbacher A; Hoetzenecker K; Idzko M; Hoda MA
    J Cancer Res Clin Oncol; 2023 May; 149(5):1747-1754. PubMed ID: 35708777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples.
    Ilié M; Hofman V; Bontoux C; Goffinet S; Benzaquen J; Heeke S; Boutros J; Lassalle S; Long-Mira E; Zahaf K; Lalvée S; Lespinet-Fabre V; Bordone O; Tanga V; Gómez-Caro A; Cohen C; Berthet JP; Marquette CH; Hofman P
    Lung Cancer; 2023 Jul; 181():107230. PubMed ID: 37150140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative Study of PD-L1 Expression in Different Sites of 
Non-small Cell Lung Cancer].
    Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
    Pan Y; Zheng D; Li Y; Cai X; Zheng Z; Jin Y; Hu H; Cheng C; Shen L; Wang J; Ji H; Sun Y; Zhou X; Chen H
    J Thorac Dis; 2017 Aug; 9(8):2579-2586. PubMed ID: 28932565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.